Press releases

11
Apr 2023
20:30 E.S.T.

Cellectis Announces Dosing of the First Patient in Europe with its In-house Manufactured Product Candidate UCART22

Read more
4
Apr 2023
20:30 E.S.T.

Cellectis enters into warrant agreement with the European Investment Bank related to credit facility agreement and announces the drawdown of the first tranche of €20 million

Read more
14
Mar 2023
21:00 E.S.T.

Cellectis Announces Poster Presentation on TALEN®-edited MUC1 CAR T-cells Targeting Triple Negative Breast Cancer at the American Association of Cancer Research (AACR) Annual Meeting

Read more
8
Mar 2023
21:45 E.S.T.

Cellectis Provides Business Update and Reports Fourth Quarter and Full Year 2022 Financial Results

Read more
6
Mar 2023
21:30 E.S.T.

Calyxt, Inc. Reports its Fourth Quarter 2022 Financial Results and Provides Corporate Update

Read more
1
Mar 2023
21:30 E.S.T.

Cellectis to Report Fourth Quarter and Year-End 2022 Financial Results on March 8, 2023

Read more
7
Feb 2023
22:32 E.S.T.

Cellectis Announces Closing of Global Offering and Exercise of Underwriters’ Option to Purchase Additional Shares

Read more
3
Feb 2023
14:41 E.S.T.

Cellectis Supplements the Announcement of the Pricing of Follow-On Offering with Allocation of Share Capital Information

Read more
2
Feb 2023
22:47 E.S.T.

Cellectis Announces Pricing of Follow-On Offering

Read more
2
Feb 2023
21:19 E.S.T.

Cellectis Announces Launch of Follow-On Offering

Read more

Press contacts

For more information on any story, or for press enquiries, get in touch with our communication team

CONTACT US